Clinical Trial

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Part 2/Phase 2a will assess the anticancer activity and safety of CHO-H01 plus lenalidomide in subjects with low-grade relapsed/refractory CD20+ non-Hodgkin's lymphoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-07-10; most recent amendment 2026-03-01.
Trial Details
NCT Number NCT05950165
Lead Sponsor Cho Pharma Inc.
Conditions Non-Hodgkin Lymphoma
Enrollment 37 participants
Start Date 2020-01-15
Primary Completion 2026-12-23 (estimated)
Study Completion 2026-12-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-03